the aid library

LIST OPTIONS

Filter

1219

Sort by:

Direction:

Download (65)

View PDF (89)

Ministerial policy dialogue on HIV and related comorbidities in eastern Europe and central Asia (EECA)

World Health Organization (Europe); Government of the Netherlands; UNAIDS (2019) C_WHO

Amsterdam, the Netherlands, 23 July 2018 Meeting Report

Download (610)

View PDF (766)

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed.
recommended

The Republic of the Union of Myanmar, Ministry of Health, Department of Health, National AIDS Programme World Health Organization (WHO), Country Office for Myanmar (2017) C1

These guidelines aim to guide all health care providers in Myanmar, accommodating the situation of different settings in the context of progressive decentralization of HIV services. Notable changes from the previous edition include:
• diagnosis of HIV
• update on the initiation of ART<... more

Download (447)

View PDF (735)

India: NATIONAL GUIDELINE FOR PARTNERSHIP

Government of India, Central Tuberculosis Division, Ministry of Health and Family Welfare (2014) C1

Download (44)

View PDF (83)

Guidelines for Dialysis of COVID – 19 patients

Government of India Ministry of Health & Family Welfare (2020) C2

COVID-19, a disease caused by a novel corona virus (SARS CoV-2), is currently a pandemic, which produces high morbidity in the elderly and in patients with associated comorbidities. Chronic kidney disease stage-5 (CKD-5) patients on dialysis [maintenance hemodialysis (MHD)or continuous ambulatory pe... more

Download (59)

View PDF (110)

Health Advisory for Elderly Population of India during COVID19 Pandemic

Ministery of Health and Family Welfare - Government of India (2020) C2

Elderly people are at a higher risk of COVID-19 infection due to their decreased immunity and body reserves, as well as multiple associated comorbidities like diabetes, hypertension, chronic kidney disease and chronic obstructive pulmonary disease. Also, course of disease tends to be more severe in ... more

Download (581)

View PDF (318)

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

World Health Organization WHO (2022) C_WHO

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more

Download (87)

View PDF (122)

Estimating mortality from COVID-19 - Scientific brief (4 August 2020)

World Health Organization WHO (2020) C_WHO

For COVID-19, as for many infectious diseases, the true level of transmission is frequently underestimated because a substantial proportion of people with the infection are undetected either because they are asymptomatic or have only mild symptoms and thus typically fail to present at healthcare fac... more

Download (361)

View PDF (443)

ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic

European Society of Cardiology (2020) C1

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) causing coronavirus disease 2019 (COVID-19) has reached pandemic levels; Patients with cardiovascular (CV) risk factors and established cardiovascular disease (CVD) represent a vulnerable population when suffering from COVID-19; Patien... more

Download (63)

View PDF (86)

Checklist and reference list for developing and reviewing a national strategic plan for HIV

UNAIDS (2020) C_WHO

The checklist and reference list has two parts: high-level cross-cutting content (Part A) and specific programme content (Part B). Part A applies to all countries and contains situation and response analysis, the NSP development process, the goal, targets and priority-setting of the NSP and the prin... more

Download (45)

View PDF (837)

Comprehensive COVID-19 Slideset: Special Populations and Comorbidities

Clinical Care Options (2021) CC

Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.

Download (224)

View PDF (218)

Evidence-based Clinical Practice Guidelines for the Follow-Up of At-Risk Neonates

Pan American Health Organisation PAHO (2021) C_WHO

Abridged version. In this abridged version of the Evidence-based Clinical Practice Guidelines for the Follow-Up of at-risk neonates, we provide recommendations for the care of newborns up to 2 years of age, corresponding to the first phase of their follow-up. The recommendations are intended for all... more

Download (40)

View PDF (182)

Tuberculosis and comorbidities in urban areas in Argentina. A gender and age perspective ,

Echazarreta, A.; Zerbini E. De Sandro j., et al. 2018 (2018) CC

180 Biomédica 2018;38:180-8

Download (79)

View PDF (103)

Tuberculosis in the Americas. Regional Report 2020

Pan American Health Organisation PAHO (2021) C_WHO

This regional report on the situation of tuberculosis (TB) in the Americas contains information from 2019, provided by the countries of the Region through the World Health Organization TB data collection system. These data have been consolidated and analyzed at the regional level. In addition to pre... more

Download (35)

View PDF (365)

Análisis epidemiológico descriptivo de pacientes diagnosticados de tuberculosis y comorbilidades asociadas, que asisten a una institución proveedora de salud en Colombia, entre 2016 y 2019

M. B. Ruíz; González Sanjuan, S.; Sánchez Sánchez, Y.; et al. (2019) CC

Describir el comportamiento epidemiológico de comorbilidades en pacientes diagnosticados con tuberculosis de una institución prestadora de servicios de salud (IPS) de Colombia, durante 2016 a 2019.

Download (92)

View PDF (129)

COVID-19 in Latin America and the caribbean region: Symptoms and morbidities in the epidemiology of infection

Anaya-Covarrubias, J.Y.; et al. (2022) C1

Curr Opin Pharmacol . 2022 Apr;63:102203.doi: 10.1016/j.coph.2022.102203. Epub 2022 Feb 11. The COVID-19 pandemic has widespread economic and social effects on Latin America (LA) and the Caribbean (CA). This region, which has a high prevalence of chronic diseases, has been one of the most affected... more

Download (55)

View PDF (1144)

Cancer in sub-Saharan Africa
recommended

Ngwa, W.; et al. Lancet Oncology Commission (2022) C2

Lancet Oncol 2022; 23: e251–312Published OnlineMay 9, 2022 https://doi.org/10.1016/S1470-2045(21)00720-8 In sub-Saharan Africa (SSA), urgent action is needed to curb a growing crisis in cancer incidence and mortality. Without rapid interventions, data estimates show a major increase in cancer mo... more

Download (58)

View PDF (472)

Self-learning course: Clinical diagnosis and management of dengue

Pan American Health Organization PAHO ; World Health Organization WHO (2021) C_WHO

This first online course is geared at helping healthcare workers in diagnosing and managing all aspects of dengue in order to avoid complications and fatalities. This course was developed with a comprehensive vision. It is divided into seven modules that include: Epidemiological informatio... more

Download (234)

View PDF (162)

A primary health care approach to obesity prevention and management in children and adolescents: policy brief

World Health Organisation (WHO) (2023) C_WHO

Obesity in all age groups, including children and adolescents, is a public health challenge across all settings. Obesity is now classified as a complex multifactorial chronic disease and not just a risk factor for other noncommunicable diseases and comorbidities. Recognizing the significance of prim... more

Download (111)

View PDF (97)

Risk factors of Cholera mortality

Global Task Force On Cholera Control (GTFCC) (2022) CC

To better adapt current case management practices and address excess mortality in otherwise treatable cases will require better knowledge of the demographic characteristics of the patients and comorbidities which can make severe dehydration harder to tolerate physiologically. With this in mind, a ... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed. recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support recommended

Cancer in sub-Saharan Africa recommended

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed.
recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

Cancer in sub-Saharan Africa
recommended